BACKGROUND AND PURPOSE: Neuronal protein S100B assays are available now with a perspective of being an early screening tool for serious intracranial injury. The aim of the study was to correlate early S100B measurements and initial CCT findings in the patients sustaining mild traumatic brain injury (MTBI). METHODS: The prospective study included patients of all ages with a history of MTBI. CCT scans and venous blood sampling for S100B analysis were performed within 6 h after injury. Levels of S100B above 0.1 ng/ml (S100B+) and any CCT detectable trauma-relevant intracranial lesions were considered positive (CCT+). RESULTS: A series of 102 patients were involved in the study. CCT+ scans were present in eighteen (17.6%) and CCT- scans in 84 (82.4%) patients. There were 74 (72.5%) patients in S100B+ and 28 (27.5%) in S100B- group. Sensitivity of S100B assay attained 83.3% with a negative predictive value of 89.3%. Three patients from CCT+ group had negative plasma level of S100B. Two of them required surgical treatment. DISCUSSION: S100B serum protein marker seems to be an unrealiable screening tool for determination of an intracranial injury risk group due to low sensitivity and negative predictive value seen from samples taken greater than 3 h after an MTBI.
BACKGROUND AND PURPOSE: Neuronal protein S100B assays are available now with a perspective of being an early screening tool for serious intracranial injury. The aim of the study was to correlate early S100B measurements and initial CCT findings in the patients sustaining mild traumatic brain injury (MTBI). METHODS: The prospective study included patients of all ages with a history of MTBI. CCT scans and venous blood sampling for S100B analysis were performed within 6 h after injury. Levels of S100B above 0.1 ng/ml (S100B+) and any CCT detectable trauma-relevant intracranial lesions were considered positive (CCT+). RESULTS: A series of 102 patients were involved in the study. CCT+ scans were present in eighteen (17.6%) and CCT- scans in 84 (82.4%) patients. There were 74 (72.5%) patients in S100B+ and 28 (27.5%) in S100B- group. Sensitivity of S100B assay attained 83.3% with a negative predictive value of 89.3%. Three patients from CCT+ group had negative plasma level of S100B. Two of them required surgical treatment. DISCUSSION: S100B serum protein marker seems to be an unrealiable screening tool for determination of an intracranial injury risk group due to low sensitivity and negative predictive value seen from samples taken greater than 3 h after an MTBI.
Authors: Linda Papa; Lawrence M Lewis; Jay L Falk; Zhiqun Zhang; Salvatore Silvestri; Philip Giordano; Gretchen M Brophy; Jason A Demery; Neha K Dixit; Ian Ferguson; Ming Cheng Liu; Jixiang Mo; Linnet Akinyi; Kara Schmid; Stefania Mondello; Claudia S Robertson; Frank C Tortella; Ronald L Hayes; Kevin K W Wang Journal: Ann Emerg Med Date: 2011-11-08 Impact factor: 5.721
Authors: Linda Papa; Lawrence M Lewis; Salvatore Silvestri; Jay L Falk; Philip Giordano; Gretchen M Brophy; Jason A Demery; Ming Cheng Liu; Jixiang Mo; Linnet Akinyi; Stefania Mondello; Kara Schmid; Claudia S Robertson; Frank C Tortella; Ronald L Hayes; Kevin K W Wang Journal: J Trauma Acute Care Surg Date: 2012-05 Impact factor: 3.313
Authors: Jeffrey J Bazarian; Brian J Blyth; Hua He; Sohug Mookerjee; Courtney Jones; Karin Kiechle; Ryan Moynihan; Susan M Wojcik; William D Grant; LaLainia M Secreti; Wayne Triner; Ronald Moscati; August Leinhart; George L Ellis; Jawwad Khan Journal: J Neurotrauma Date: 2013-08-24 Impact factor: 5.269
Authors: Linda Papa; Michelle M Ramia; Jared M Kelly; Stephen S Burks; Artur Pawlowicz; Rachel P Berger Journal: J Neurotrauma Date: 2013-02-15 Impact factor: 5.269